Next Article in Journal
Marfan Syndrome Versus Bicuspid Aortic Valve Disease: Comparative Analysis of Obstetric Outcome and Pregnancy-Associated Immediate and Long-Term Aortic Complications
Previous Article in Journal
Predicting Stroke Outcomes Using Ankle-Brachial Index and Inter-Ankle Blood Pressure Difference
Open AccessEditorial

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

1
University Lyon 1, Laboratory “Health Systemic Process”, EA4129, 69008 Lyon, France
2
Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy
3
THEnet, Training for Health Equity Network, New York, NY 10023, USA
4
Faculty of Dentistry, Estacio de Sá University, Rio de Janeiro 20261-063, Brazil
5
Lyon Public Hospices, Central Pharmacy, EA4129, 69002 Lyon, France
6
Department of Preventive and Community Dentistry, University of Granada, 18010 Granada, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 1126; https://doi.org/10.3390/jcm9041126
Received: 27 March 2020 / Accepted: 13 April 2020 / Published: 15 April 2020
(This article belongs to the Special Issue The Oral Microbiome in Health and Disease)
Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression. View Full-Text
Keywords: COVID-19; 2019-nCoV; SARS-CoV-2; oral cavity; mouthrinse; β-cyclodextrins; Citrox; viral load; microbiome COVID-19; 2019-nCoV; SARS-CoV-2; oral cavity; mouthrinse; β-cyclodextrins; Citrox; viral load; microbiome
MDPI and ACS Style

Carrouel, F.; Conte, M.P.; Fisher, J.; Gonçalves, L.S.; Dussart, C.; Llodra, J.C.; Bourgeois, D. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. J. Clin. Med. 2020, 9, 1126.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop